Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent

IL-31 Inhibitor On File In US And EU

Galderma presented long-term extension data from its Phase III trials in atopic dermatitis and prurigo nodularis at AAD for its first-ever therapeutic biologic, taking on a formidable competitor.

Different light bulb glowing in a line
Galderma is set to position nemolizumab as a unique option • Source: Shutterstock

Galderma S.A. will launch its first-ever therapeutic biologic in 2024, assuming US Food and Drug Administration approval is granted later this year, and presented long-term data at the American Academy of Dermatology (AAD) meeting in San Diego that it believes will make the case for preferential use of its IL-31 receptor alpha inhibitor nemolizumab in prurigo nodularis (PN) and in certain Dupixent (dupilumab)-treated and -naïve patients with atopic dermatitis (AD).

Key Takeaways
  • Galderma reported positive longer-term data for its IL-31 inhibitor nemolizumab in prurigo nodularis (PN) and atopic dermatitis (AD) that it believes differentiate the drug, including versus market leader Dupixent (dupilumab).

The private Swiss company, which announced on 6 March that it plans to go public on the SIX Swiss Exchange,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza